Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 85, Issue 4, 2013, Pages 1012-1017

  Zumsteg, Zachary S ^a   Spratt, Daniel E ^a   Pei, Xin ^a   Yamada, Yoshiya ^a   Kalikstein, Abraham ^a   Kuk, Deborah ^a   Zhang, Zhigang ^a   Zelefsky, Michael J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COX PROPORTIONAL HAZARDS MODELS; EXTERNAL BEAM RADIATION THERAPY; INDEPENDENT PREDICTORS; METHODS AND MATERIALS; MULTI VARIATE ANALYSIS; PROSTATE SPECIFIC ANTIGEN; RECURRENCE-FREE SURVIVAL; UNIVARIATE ANALYSIS;

DISEASES; RADIOTHERAPY;

RISK ANALYSIS;

ANDROGEN RECEPTOR ANTAGONIST; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER MORTALITY; CANCER RISK; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE ESCALATION; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT;

AGE FACTORS; AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; RISK;

EID: 84875214812     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.07.2374     Document Type: Article

References (20)

1. Z.S. Zumsteg, and M.J. Zelefsky Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care? Lancet Oncol 13 2012 e259 e269
2. C.U. Jones, D. Hunt, and D.G. McGowan Radiotherapy and short-term androgen deprivation for localized prostate cancer N Engl J Med 365 2011 107 118
3. A.V. D'Amico, M.H. Chen, and A.A. Renshaw Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial JAMA 299 2008 289 295
4. A.L. Zietman, K. Bae, and J.D. Slater Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09 J Clin Oncol 28 2010 1106 1111
5. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487
6. M.G. Sanda, R.L. Dunn, and J. Michalski Quality of life and satisfaction with outcome among prostate-cancer survivors N Engl J Med 358 2008 1250 1261
7. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456
8. R.K. Valicenti, K. Bae, and J. Michalski Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06 Int J Radiat Oncol Biol Phys 79 2011 1323 1329
9. D. Krauss, L. Kestin, and H. Ye Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer Int J Radiat Oncol Biol Phys 80 2011 1064 1071
10. B. Dubray, V. Beckendorf, and S. Guerif Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediate analysis of GETUG 14 randomized trial (EU-20503/NCT00104741) [abstract] J Clin Oncol 2011 29
11. M.J. Zelefsky, X. Pei, and J.F. Chou Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes Eur Urol 60 2011 1133 1139
12. M.J. Zelefsky, H. Chan, and M. Hunt Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer J Urol 176 2006 1415 1419
13. M.J. Zelefsky, V.E. Reuter, and Z. Fuks Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer J Urol 179 2008 1368 1373
14. J.W. Denham, A. Steigler, and D.S. Lamb Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial Lancet Oncol 12 2011 451 459
15. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
16. M. Bolla, G. Van Tienhoven, and P. Warde External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study Lancet Oncol 11 2010 1066 1073
17. A.V. D'Amico, A.A. Renshaw, and K. Cote Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease J Clin Oncol 22 2004 3726 3732
18. J.R. Stark, S. Perner, and M.J. Stampfer Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27 2009 3459 3464
19. M.J. Zelefsky, J.F. Chou, and X. Pei Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: the Memorial Sloan-Kettering Cancer Center experience Brachytherapy 11 2012 245 249
20. R.G. Stock, S. Yalamanchi, and S.J. Hall Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation J Urol 183 2010 546 550